Atherosclerosis and its complications are the result of complex interactions between the environment and genetic factors. Platelets play an important role in this disease process and antiplatelet agents are an essential part of its treatment. However, ...
The possibility that infection is a stimulus for the vascular inflammation that promotes atherogenesis has spawned clinical trials of antibiotics. These have focused primarily on Chlamydia pneumoniae as a potential atherogenic agent. In contrast to pilot ...
Atherosclerosis is a type of chronic inflammatory disease characterized by the presence of monocyte-derived cells in all stages. Monocytes, macrophages, dendritic and foam cells play important roles in the uptake of oxidized lipids, lesion development, ...
The cytochrome (CYP) P450 epoxygenase pathway catalyzes the epoxidation of arachidonic acids to epoxyeicosatrienoic acids, which are subsequently hydrolyzed to less active dihydroxyeicosatrienoic acids by soluble epoxide hydrolase. Numerous preclinical ...
The metabolic syndrome is defined as a clustering of cardiovascular risk factors with insulin resistance, including dyslipidemia, coagulation disturbances and hypertension. Activators of the peroxisome proliferator-activated receptors (PPARs) modulate ...
Nitric oxide functions as a signaling molecule with a well-established role in vascular homeostasis. It is synthesized from the oxidation of L-arginine by the enzyme, endothelial nitric oxide synthase (eNOS). The eNOS gene has a number of polymorphic ...
Inflammation plays a key role in Alzheimer disease, and dissecting the genetics of inflammation may provide an answer to the possible treatment. The next-generation therapy is based on a pharmacogenomics that will reconure new approaches to a drug used on ...
A non-optimal plasma concentration of lipids is among the major modifiable risk factors of atherosclerosis. Therefore, the prevention of cardiovascular disease by means of lipid-lowering therapy with statins and other agents is of great importance for ...
Endothelial dysfunction, including impaired vasomotor disturbance, abnormal coagulation, and increased vascular proliferation, is closely associated with the development of atherosclerosis and precedes the clinical manifestations of atherosclerosis. The ...
Evidence for the role of lipoprotein(a) (Lp[a]) in atherosclerosis and thrombosis has considerably increased over the past few years. Therefore, Lp(a) is currently classified as an emerging lipid risk factor for cardiovascular disease. High Lp(a) plasma ...
Adiponectin may play a role in the pathophysiology of atherosclerosis, dyslipidemia and coronary artery disease. Thus, adiponectin administration diminishes atherosclerotic burden in experimental mouse models and high plasma adiponectin concentrations are ...
The oxidation hypothesis of atherosclerosis suggests that oxidative modification of low-density lipoprotein (LDL) is a prerequisite for LDL atherogenicity. Recent studies demonstrate that upon oxidative modification, LDL becomes enriched with pathogen-...
Despite primary and secondary prevention, serious cardiovascular events such as unstable angina or myocardial infarction still account for a third of all deaths worldwide. Therefore, identifying individual patients with vulnerable plaques at high risk for ...
The role of high-density lipoprotein (HDL) in the genesis and evolution of cardiovascular disease is a topical and interesting issue. Reduced HDL concentrations appear to be unable to efficiently eliminate the cholesterol excess at the vascular wall level,...
Atherosclerosis remains the primary cause of heart disease and stroke, causing approximately 50% of all deaths in Western countries. The identification of promising novel anti-atherosclerotic therapies is therefore of great interest and represents a ...
Atherosclerosis is caused by a series of pathologic changes at the cellular level, with formation of macrophage-derived foam cells occurring at an early stage. Most of the cholesteryl esters in macrophage foam cells are produced by the enzyme acyl-...
Cardiovascular disease (CVD) is extremely complex. It results from the interaction of many genetic and environmental factors. Several studies have demonstrated its genetic basis, estimating a heritability of approximately 60%. In the last 5 years, at ...
Currently, most pharmacological therapies for atherosclerosis rely on lowering plasma low-density lipoprotein levels. Several ongoing clinical trials are testing the possibility of reducing atherosclerosis with drugs that raise plasma high-density ...
Evaluation of: Llodrá J, Angeli V, Liu J, Trogan E, Fisher AE, Randolph GJ: Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl Acad. Sci. 101(32), 11779–11784 (2004). ...